Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage (phage) therapeutics for antibiotic-resistant infections using its proprietary phage-based technology. Armata’s lead product candidate, AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. The Company is also developing and advancing a broad pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. In collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is headquartered in Marina del Rey, California, with a 35,000 square foot facility housing R&D and phage-specific GMP manufacturing. More information is available at www.armatapharma.com
Biotechnology, Therapeutics, Drug Development, Infectious Disease, Microbiome, Targeted Antimicrobials, Bacteriophage, Synthetic Biology, Engineered Phage, targeted phage-based drugs, antimicrobial peptides, Phage, Synthetic Biology, Clinical-Stage
Marina del Rey, CA, United States